Benign Conditions

Benign Prostatic Hyperplasia

Bladder Cancer

Female Urology

Genitourinary Cancers

Genomic Testing

Hormone Therapy

Kidney Cancer

Challenging Anatomy

Innovative Techniques

Laser Lithotripsy

PCNL Tech & Devices

Ureteroscopy Tech & Devices

Kidney Stones

Men's Health

Next-Generation Imaging

Voiding Dysfunction

OAB and Incontinence

Pediatrics

Controveries in Urologic Cancer

Drug Therapy

Prostate Cancer

Sexual Dysfunction

UTUC

Cosmetic Surgery

Urologic Surgery

Business

Practice Management

Malpractice Consult

Health Law & Policy

Media

Case-Based Peer Perspectives

Investigator Perspectives 

Medical World News

Podcasts

Urology Medical Perspectives

UTv Videos

Peer Exchange

Special Report

Virtual Tumor Board

Insights

Medcast

Peers & Perspectives

Conferences

Conference Listing

Conference Previews 

Conference Recaps

Publications

Urology Times Journal

Editorial Advisory Board

Urologists in Cancer Care

Supplements and Featured Publications

Clinical Forums Recaps

CME/CE

Resources

Begin Your Journey: Tackling Burnout

Live Events

Interactive Tools

Job Board

Partners

Treatment Landscape Evolutions

Subscribe

Articles

Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.

In a panel meeting convened by the FDA, experts urged the agency to revise or remove the outdated boxed warning on hormone therapies for menopause.

Experts urge FDA to remove black box warning on low-dose vaginal estrogen 

In both cohorts, the combination of talazoparib plus enzalutamide led to a significant improvement in overall survival vs enzalutamide alone.

Phase 3 TALAPRO-2 data of talazoparib plus enzalutamide published in The Lancet

Take a look back through some of the top stories from the first half of the year.

Urology in focus: Key moments from 2025

The phase 2 Co-PSMA trial enrolled 50 patients with biochemical recurrence of prostate cancer.

Enrollment goal met in trial of 64Cu-SAR-bisPSMA vs. 68Ga-PSMA-11 PET/CT

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do not sell my Personnal Information

Urology Times – News & Insights for Urologists & Health Professionals

Facebook

LinkedIn

Spotlight

Peers and Perspectives

Clinical

1rem

View

Deep Data Dive: Highlights From ASCO 2024 on the Treatment of High-Risk BCG-Unresponsive NMIBC

Video Series

Impact of BCG Therapy Shortage on the Management of High-Risk NMIBC

Video content above is prompted by the following:

Can you describe the current shortage of bacillus Calmette-Guerin, or BCG, therapy; how has this has impacted your clinical practice and management of high-risk NMIBC?

Videos

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, discuss key conversation points surrounding high-risk BCG-unresponsive NMIBC as presented at ASCO 2024 in Chicago, Illinois.

After briefly introducing themselves, Trinity Bivalacqua, MD, PhD and Mark Tyson, MD, MPH discuss approximately how many newly diagnosed bladder cancer patients have non-muscle invasive bladder cancer, or NMIBC.

Prevalence and Staging of Newly Diagnosed Bladder Cancer

Trinity Bivalacqua, MD, PhD and Mark Tyson, MD, MPH discuss the current shortage of BCG therapy and how that has impacted clinical practice management.

Experts discuss the rate of recurrence following first-line BCG therapy.

Recurrence and BCG Resistance in High-Risk NMIBC

Experts discuss available therapies beyond BCG.

Therapies Beyond BCG: FDA-Approved and Emerging Options

Experts give an overview of the ASCO 2024 data. 

Cretostimogene, Grenadenorepvec, and Pembrolizumab for BCG-Unresponsive NMIBC: Overview of ASCO 2024 Data

Experts discuss the patient quantity and qualifications for the CORE-001 trial.

CORE-001 Trial Participation and Eligibility Criteria

Experts compare Cretostimogene and BCG Administration Methods

Comparing Cretostimogene and BCG Administration Methods

Experts discuss the results of the CORE-001 Trial. 

Results of the CORE-001 Trial: 24-Month Complete Response Rate and Duration of Response

Key opinion leaders examine the comparative safety profiles and response durations of combination therapy versus monotherapy in the treatment of BCG-unresponsive carcinoma in situ with or without papillary disease.

Safety Outcomes and Duration of Response in Combination Therapy vs. Monotherapy for BCG UR CIS +/- Papillary Disease

Panelists discuss how the combination therapy of cretostimogene plus pembrolizumab offers a promising new approach for managing BCG-unresponsive non-muscle-invasive bladder cancer, highlighting its potential benefits and the implications of its FDA Breakthrough Therapy Designation for clinical practice.

Evaluating the Benefits of Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC Management

Panelists discuss whether the trial results support investigating cretostimogene with other checkpoint inhibitors and provide insights into notable ongoing trials exploring cretostimogene for intermediate- or high-risk NMIBC, such as BOND-003 and PIVOT-006.

Evaluating Cretostimogene: BOND-003 and PIVOT-006 Trial Results

Panelists discuss their views on using cretostimogene as monotherapy versus combination therapy, the importance for urologists to stay updated on advances for managing BCG-unresponsive NMIBC, and the potential impact of combining cretostimogene with pembrolizumab on addressing unmet needs in NMIBC care.

Managing BCG-Unresponsive NMIBC: Cretostimogene Monotherapy vs. Combination Therapy

Impact of BCG Therapy Shortage on the Management of High-Risk NMIBC

EP: 1.Prevalence and Staging of Newly Diagnosed Bladder Cancer

EP: 2.Impact of BCG Therapy Shortage on the Management of High-Risk NMIBC

EP: 3.Recurrence and BCG Resistance in High-Risk NMIBC

EP: 4.Therapies Beyond BCG: FDA-Approved and Emerging Options

EP: 5.Cretostimogene, Grenadenorepvec, and Pembrolizumab for BCG-Unresponsive NMIBC: Overview of ASCO 2024 Data

EP: 6.CORE-001 Trial Participation and Eligibility Criteria

EP: 7.Comparing Cretostimogene and BCG Administration Methods

EP: 8.Results of the CORE-001 Trial: 24-Month Complete Response Rate and Duration of Response

EP: 9.Safety Outcomes and Duration of Response in Combination Therapy vs. Monotherapy for BCG UR CIS +/- Papillary Disease

EP: 10.Evaluating the Benefits of Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC Management

EP: 11.Evaluating Cretostimogene: BOND-003 and PIVOT-006 Trial Results

EP: 12.Managing BCG-Unresponsive NMIBC: Cretostimogene Monotherapy vs. Combination Therapy

Newsletter